NCT00806351View on ClinicalTrials.gov

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

PHASE3TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
FungemiaNeutropeniaCandidiasis
Interventions
DRUG

Active Anidulafungin

Subjects in this arm will receive active anidulafungin and placebo caspofungin

DRUG

Active Caspofungin

Subjects in this arm will receive active caspofungin and placebo anidulafungin

Trial Locations (10)

38043

Pfizer Investigational Site, Grenoble

40138

Pfizer Investigational Site, Bologna

67098

Pfizer Investigational Site, Strasbourg

71000

Pfizer Investigational Site, Sarajevo

115478

Pfizer Investigational Site, Moscow

00133

Pfizer Investigational Site, Roma

80-952

Pfizer Investigational Site, Gdansk

02-776

Pfizer Investigational Site, Warsaw

50-367

Pfizer Investigational Site, Wroclaw

04190

Pfizer Investigational Site, Košice

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY